Chemokines and other cytokines in human immunodeficiency virus type 1 (HIV-1) infection

Inmunologia

Volumn 24, Issue 2, 2005, Pages 246-260

  Llano, A ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Chemokine; Cytokine; HIV 1

Indexed keywords

ARGININE; CCL 3 CHEMOKINE; CCL4 CHEMOKINE; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 1; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; PIPERAZINE DERIVATIVE; RANTES; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL TYPE; CYTOKINE PRODUCTION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VIVO STUDY; PROTEIN EXPRESSION; REVIEW; VIRUS REPLICATION;

EID: 23644446464     PISSN: 02139626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat Med 1996;2:1293-300.
2. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-8.
3. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15.
4. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001;2:102-7.
5. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001;2:95-101.
6. Mellado M, Rodríguez-Frade JM, Manes S, Martínez AC. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 2001;19:397-421.
7. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
8. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7.
9. Mackay CR. Chemokine receptors and T cell chemotaxis. J Exp Med 1996;184:799-802.
10. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-767.
11. Reinherz EL, Kung PC, Goldstein G, Schlossman SF. Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci U S A 1979;76:4061-4065.
12. Maddon PJ, Littman DR, Godfrey M, Maddon DE, Chess L, Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell 1985;42:93-104.
13. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995;85:475-484.
14. Jordan CA, Watkins BA, Kufta C, Dubois-Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991;65(2):736-742.
15. Ashorn PA, Berger EA, Moss B. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol 1990;64(5):2149-2156.
16. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
17. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP et al. A new classification for HIV-1. Nature 1998;391:240.
18. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-835.
19. Bleui CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-1109.
20. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
21. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
22. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
23. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997;234:340-348.
24. Signoret N, Oldridge J, Pelchen-Matthews A, Klasse PJ, Tran T, Brass LF et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997;139:651-664.
25. Vila-Coro AJ, Mellado M, Martín de Ana A, Lucas P, del Real G, Martínez AC et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A 2000;97:3388-3393.
26. Hernanz-Falcón P, Rodríguez-Frade JM, Serrano A, Juan D, del Sol A, Soriano SF et al. Identification of amino acid residues crucial for chemokine receptor dimerization. Nat Immunol 2004;5:216-223.
27. Rodríguez-Frade JM, del Real G, Serrano A, Hernanz-Falcon P, Soriano SF, Vila-Coro AJ et al. Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. Embo J 2004;23:66-76.
28. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
29. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply- exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
30. Michael NL, Nelson JA, KewalRamani VN, Chang G, O'Brien SJ, Mascola JR et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998;72:6040-6047.
31. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
32. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998;352:866-870.
33. Quillent C, Oberlin E, Braun J, Rousset D, González-Canali G, Metais P, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998;35:14-28.
34. Hernández PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHM syndrome, a combined immunodeficiency disease. Nat Genet 2003;34:70-74.
35. Nagasawa T. Role of chemokine SDF-1/PBSF and its receptor CXCR4 in blood vessel development. Ann N Y Acad Sci 2001;947:112-5.
36. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-1691.
37. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 1997;3:1369-1375.
38. Granelli-Piperno A, Moser B, Pope M, Chen D, Wei Y, Isdell F, et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med 1996;184:2433-2438.
39. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997;94:1925-1930.
40. Mo H, Monard S, Pollack H, Ip J, Rochford G, Wu L et al. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses 1998;14:607-617.
41. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005;434:1093-1097.
42. Graziosi C, Pantaleo G, Demarest JF, Cohen OJ, Vaccarezza M, Butini L et al. HIV-1 infection in the lymphoid organs. AIDS 1993;7.
43. Frost SD, McLean AR. Germinal centre destruction as a major pathway of HIV pathogenesis. J Acquir Immune Defic Syndr 1994;7:236-244.
44. Lombardi VR, Maneiro E, Cacabelos R. Central nervous system damage during HIV infection. Methods Find Exp Clin Pharmacol 1996;18:707-722.
45. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005;365:1031-1038.
46. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005;434:1148-1152.
47. Connor RI, Ho DD. Transmission and pathogenesis of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:321-323.
48. Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
49. van't Wout AB, Blaak H, Ran LJ, Brouwer M, Kuiken C, Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J Virol 1998;72:5099-5107.
50. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-1360.
51. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T- lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993;67:1772-1777.
52. Bomsel M, David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med 2002;8:114-116.
53. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 1998;153:481-490.
54. Lee B, Ratajczak J, Doms RW, Gewirtz AM, Ratajczak MZ. Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Blood 1999;93:1145-1156.
55. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 2003;100:8401-8406.
56. Agace WW, Amara A, Roberts AI, Pablos JL, Thelen S, Uguccioni M et al. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000;10:325-328.
57. Pohlmann S, Baribaud F, Doms RW. DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol 2001;22:643-646.
58. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002;16:135-144.
59. Tamalet C, Lafeuillade A, Yahi N, Vignoli C, Tourres C, Pellegrino P et al. Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood. AIDS 1994;8:1083-1088.
60. Derdeyn CA, Costello C, Kilby JM, Sfakianos G, Saag MS, Kaslow R et al. Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. AIDS Res Hum Retroviruses 1999;15:1063-1071.
61. Soriano A, Martínez C, García F, Plana M, Palou E, Lejeune M et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3′A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002;186:922-931.
62. Ikegawa M, Yuan J, Matsumoto K, Herrmann S, Iwamoto A, Nakamura T et al. Elevated plasma stromal cell-derived factor 1 protein level in the progression of hiv type 1 infection/aids. AIDS Res Hum Retroviruses 2001;17:587-595.
63. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998;279:389-393.
64. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12:F85-90.
65. Brambilla A, Villa C, Rizzardi G, Veglia F, Ghezzi S, Lazzarin A et al. Shorter Survival of SDF1-3′A/3′A Homozygotes Linked to CD4+ T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection. J Infect Dis 2000;182:311-315.
66. Llano A, Barretina J, Blanco J, Gutiérrez A, Clotet B, Esté JA. Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. AIDS 2001;15:1890-1892.
67. Malnati MS, Tambussi G, Clerici E, Polo S, Algeri M, Nardese V et al. Increased plasma levels of the C-C chemokine RANTES in patients with primary HIV-1 infection. J Biol Regul Homeost Agents 1997;11:40-42.
68. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998;177:1091-1096.
69. Saha K, Bentsman G, Chess L, Volsky DJ. Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non- syncytium-inducing HIV-1 in vitro. J Virol 1998;72:876-881.
70. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, et al. Higher macrophage inflammatory protein (MIP)-1 alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A 2000;97:13812-13817.
71. Clerici M, Balotta C, Trabattoni D, Papagno L, Ruzzante S, Rusconi S, et al. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 1996;10:1432-1433.
72. Scala E, D'Offizi G, Rosso R, Turriziani O, Ferrara R, Mazzone AM et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997;158:4485-4492.
73. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102:223-231.
74. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587-592.
75. Grivel JC, Ito Y, Faga G, Santoro F, Shaheen F, Malnati MS et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med 2001;7:1232-1235.
76. Mayanja-Kizza H, Wajja A, Wu M, Peters P, Nalugwa G, Mubiru F et al. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2001;183:1801-1804.
77. Giménez-Barcons M, Ribera M, Llano A, Clotet B, Esté JA, Martínez MA. Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection. Clin Infect Dis 2005;40:1342-1349.
78. Vlahakis SR, Villasis-Keever A, Gómez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002;169:5546-5554.
79. Marozsan AJ, Torre VS, Johnson M, Ball SC, Cross JV, Templeton DJ et al. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J Virol 2001;75:8624-8638.
80. Kelly MD, Naif HM, Adams SL, Cunningham AL, Lloyd AR. Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages. J Immunol 1998;160:3091-3095.
81. Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc Natl Acad Sci U S A 1998;95:11880-11885.
82. Dolei A, Biolchini A, Serra C, Curreli S, Gomes E, Dianzani F. Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor4 induction in T cells treated with macrophage inflammatory protein (MIP)-1 alpha, MIP-1beta and RANTES beta-chemokines. AIDS 1998;12:183-190.
83. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 2003;307:122-134.
84. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998;187:601-608.
85. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 1998;95:3117-3121.
86. Matsumoto T, Miike T, Nelson RP, Trudeau WL, Lockey RF, Yodoi J. Elevated serum levels of IL-8 in patients with HIV infection. Clin Exp Immunol 1993;93:149-151.
87. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
88. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, Saag MS et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A 1996;93:4386-4391.
89. Rinaldo CR, Jr., Armstrong JA, Kingsley LA, Zhou S, Ho M. Relation of alpha and gamma interferon levels to development of AIDS in homosexual men. J Exp Pathol 1990;5(3):127-32.
90. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-765.
91. Patella V, Florio G, Petraroli A, Marone G. HIV-1 gp120 induces IL-4 and IL-13 release from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. J Immunol 2000;164:589-595.
92. Ameglio F, Capobianchi MR, Castilletti C, Cordiali Fei P, Fais S, Trente E et al. Recombinant gp120 induces IL-10 in resting peripheral blood mononuclear cells; correlation with the induction of other cytokines. Clin Exp Immunol 1994;95:455-458.
93. Capobianchi MR, Barresi C, Borghi P, Gessani S, Fantuzzi L, Ameglio F et al. Human immunodeficiency virus type 1 gp120 stimulates cytomegalovirus replication in monocytes: possible role of endogenous interleukin-8. J Virol 1997;71:1591-1597.
94. Francis ML, Meltzer MS. Induction of IFN-alpha by HIV-1 in monocyte-enriched PBMC requires gp120-CD4 interaction but not virus replication. J Immunol 1993;151:2208-2216.
95. Chen P, Mayne M, Power C, Nath A. The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem 1997;272:22385-22388.
96. Lim SP, Garzino-Demo A. The human immunodeficiency virus type 1 Tat protein up-regulates the promoter activity of the beta-chemokine monocyte chemoattractant protein 1 in the human astrocytoma cell line U-87 MG: role of SP-1, AP-1, and NF-kappaB consensus sites. J Virol 2000;74:1632-1640.
97. Westendorp MO, Li-Weber M, Frank RW, Krammer PH. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 1994;68:4177-4185.
98. Quaranta MG, Camponeschi B, Straface E, Malorni W, Viora M. Induction of interleukin-15 production by HIV-1 nef protein: a role in the proliferation of uninfected cells. Exp Cell Res 1999;250:112-121.
99. Brigino E, Haraguchi S, Koutsonikolis A, Cianciolo GJ, Owens U, Good RA et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc Natl Acad Sci U S A 1997;94:3178-3182.
100. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
101. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
102. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
103. Patterson BK, Czerniewski M, Andersson J, Sullivan Y, Su F, Jiyamapa D et al. Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Clin Immunol 1999;91:254-262.
104. Jourdan P, Abbal C, Nora N, Hori T, Uchiyama T, Vendrell JP, et al. IL-4 induces functional cell-surface expression of CXCR4 on human T cells. J Immunol 1998;160:4153-4157.
105. Meyer-Hoffert U, Lezcano-Meza D, Bartels J, Montes-Vizuet AR, Schroder JM, Teran LM. Th2- and to a lesser extent Th1-type cytokines upregulate the production of both CXC (IL-8 and gro-alpha) and CC (RANTES, eotaxin, eotaxin-2, MCP-3 and MCP-4) chemokines in human airway epithelial cells. Int Arch Allergy Immunol 2003;131:264-271.
106. Wright KM, Friedland JS. Complex patterns of regulation of chemokine secretion by Th2-cytokmes, dexamethasone, and PGE2 in tuberculous osteomyelitis. J Clin Immunol 2003;23:184-193.
107. Moonis M, Lee B, Bailer RT, Luo Q, Montaner LJ. CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells. AIDS 2001;15:1941-1949.
108. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes Infect 2004;6:1273-1277.
109. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000;18:529-560.
110. Gudmundsdottir H, Turka LA. A closer look at homeostatic proliferation of CD4+ T cells: costimulatory requirements and role in memory formation. J Immunol 2001;167:3699-3707.
111. Cohen Stuart J, Hamann D, Borleffs J, Roos M, Miedema F, Boucher C, et al. Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. AIDS 2002;16:2263-2266.
112. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998;101:2301-2308.
113. Ruiz-Mateos E, de la Rosa R, Franco JM, Martínez-Moya M, Rubio A, Soriano N et al. Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy. AIDS 2003;17:947-954.
114. Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000;181:141-147.
115. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695.
116. Okamoto Y, Douek DC, McFarland RD, Koup RA. Effects of exogenous interleukin-7 on human thymus function. Blood 2002;99:2851-2858.
117. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003;101:2294-2249.
118. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 2001;97:1525-1533.
119. Gutierrez-Ramos JC, Olsson C, Palacios R. Interleukin (IL1 to IL7) gene expression in fetal liver and bone marrow stromal clones: cytokine-mediated positive and negative regulation. Exp Hematol 1992;20:986-990.
120. Madrigal-Estebas L, McManus R, Byrne B, Lynch S, Doherty DG, Kelleher D et al. Human small intestinal epithelial cells secrete interleukin-7 and differentially express two different interleukin-7 mRNA Transcripts: implications for extrathymic T-cell differentiation. Hum Immunol 1997;58:83-90.
121. Heufler C, Topar G, Grasseger A, Stanzl U, Koch F, Romani N et al. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med 1993;178:1109-1114.
122. de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gafflard C, Vanbervliet B, Ait-Yahia S et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998;160:1666-1676.
123. Sudo T, Ito M, Ogawa Y, Iizuka M, Kodama H, Kunisada T et al. Interleukin 7 production and function in stromal cell-dependent B cell development. J Exp Med 1989;170:333-338.
124. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-432.
125. Plum J, De Smedt M, Leclercq G, Verhasselt B, Vandekerckhove B. Interleukin-7 is a critical growth factor in early human T-cell development. Blood 1996;88:4239-4245.
126. Yu Q, Erman B, Park JH, Feigenbaum L, Singer A. IL-7 Receptor Signals Inhibit Expression of Transcription Factors TCF-1, LEF-1, and ROR{gamma}t: Impact on Thymocyte Development. J Exp Med 2004;200:797-803.
127. Grabstein KH, Namen AE, Shanebeck K, Voice RF, Reed SG, Widmer MB. Regulation of T cell proliferation by IL-7. J Immunol 1990;144:3015-3020.
128. Gringhuis SI, de Leij LF, Verschuren EW, Borger P, Vellenga E. Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1. Blood 1997;90:2690-2700.
129. Jourdan P, Vendrell JP, Huguet MF, Segondy M, Bousquet J, Pene J et al. Cytokines and cell surface molecules independently induce CXCR4 expression on CD4+ CCR7+ human memory T cells. J Immunol 2000;165:716-724.
130. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 2001;10:10.
131. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 2001;97:1491-1497.
132. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001;7:73-79.
133. Llano A, Barretina J, Gutiérrez A, Blanco J, Cabrera C, Clotet B et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001;75:10319-10325.
134. Llano A, Barretina J, Gutiérrez A, Clotet B, Esté JA. Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. J Virol 2003;77:4389-4395.
135. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115:128-137.
136. Correa R, Resino S, Muñoz-Fernández MA. Increased interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected children. J Clin Immunol 2003;23:401-406.
137. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-655.
138. Ducrey-Rundquist O, Guyader M, Trono D. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol 2002;76:9103-9111.
139. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002;76:13077-13082.
140. Nugeyre MT, Monceaux V, Beq S, Cumont MC, Ho Tsong Fang R, Chene L et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol 2003;171:4447-4453.
141. Dardalhon V, Jaleco S, Kinet S, Herpers B, Steinberg M, Ferrand C et al. IL-7 differentially regulates cell cycle progression and HIV-1-based vector infection in neonatal and adult CD4+ T cells. Proc Natl Acad Sci U S A 2001;98:9277-9282.
142. Pedroza-Martins L, Boscardin WJ, Anisman-Posner DJ, Schols D, Bryson YJ, Uittenbogaart CH. Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants. J Virol 2002;76:6929-6943.
143. Esté JA. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003;10:1617-1632.
144. Bleui CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-833.
145. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997;186:139-146.
146. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
147. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
148. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 1998;95:14500-14505.
149. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S et al. The CC chemokine 1-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 1998;273:386-391.
150. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998;187:1215-1224.
151. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
152. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-1393.
153. Cabrera C, Gutiérrez A, Barretina J, Blanco J, Litovchick A, Lapidot A et al. Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Res 2002;53:1-8.
154. Cabrera C, Gutiérrez A, Blanco J, Barretina J, Litovchick A, Lapidot A et al. Anti-human immunodeficiency virus activity of novel aminoglycoside- arginine conjugates at early stages of infection. AIDS Res Hum Retroviruses 2000;16:627-634.
155. Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000;57:116-124.
156. Esté JA, Cabrera C, De Clercq E, Struyf S, Van Damme J, Bridger G et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol Pharmacol 1999;55:67-73.
157. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
158. Schols D, Esté JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35(3):147-56.
159. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
160. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-587.
161. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 2003;17:17.
162. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999;96:5698-5703.
163. Esté JA. TAK-779 (Takeda). Curr Opin Investig Drugs 2001;2:354-356.
164. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001;13:13.
165. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L et al. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140. J. Virol. 2001;75:579-588.
166. Baroudy BM. Second generation CCR5 antagonist that inhibits HIV-1 entry. In: The 1st IAS Conference on HIV Pathogenesis and Treatment 2001; Buenos Aires, 2001.
167. Martínez MA, Clotet B, Esté JA. RNA interference of HIV replication. Trends Immunol 2002;23:559-561.
168. Martínez MA, Gutiérrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002;16:2385-2390.
169. Veazey RS, Lackner AA. HIV swiftly guts the immune system. Nat Med 2005;11:469-470.
170. Picker LJ, Watkins DI. HIV pathogenesis: the first cut is the deepest. Nat Immunol 2005;6:430-432.
171. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev 2001;65:131-150.
172. Shapiro L, Puren AJ, Barton HA, Novick D, Peskind RL, Shenkar R et al. Interleukin 18 stimulates HIV type 1 in monocytic cells. Proc Natl Acad Sci U S A 1998;95:12550-12555.
173. Klein SA, Klebba C, Kauschat D, Pape M, Ozmen L, Hoelzer D et al. Interleukin-18 stimulates HIV-1 replication in a T-cell line. Eur Cytokine Netw 2000;11:47-52.
174. Amiel C, Darcissac E, Truong MJ, Dewulf J, Loyens M, Mouton Y et al. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J Infect Dis 1999;179:83-91.
175. Forcina G, D'Ettorre G, Mastroianni CM, Carnevalini M, Scorzolini L, Ceccarelli G et al. Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy. Cytokine 2004;25:283-290.
176. Ahmad R, Sindhu ST, Toma E, Morisset R, Ahmad A. Studies on the production of IL-15 in HIV-infected/AIDS patients. J Clin Immunol 2003;23:81-90.
177. Kanai T, Thomas EK, Yasutomi Y, Letvin NL. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol 1996;157:3681-3687.